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EXECUTIVE SUMMARY  
 
The Endocrine Disrupters Expert Advisory Group (ED EAG) was established in November 2011 as a 
sub-group of the ad hoc group of Commission Services, EU Agencies and Member States for the 
Community Strategy on Endocrine Disrupters. The main role of the ED EAG is to provide detailed 
reflections on scientific issues relevant to endocrine disrupting substances, not specific to any 
regulatory framework, including advice/orientation on scientific criteria for the identification of 
endocrine disrupting substances.  
 
The ED EAG is composed of toxicologists and ecotoxicologists with regulatory and/or endocrinology 
backgrounds, nominated by Member State Competent Authorities for REACH (CARACAL) and the 
Plant Protection Products Regulation (PPPR) (Standing Committee), relevant industry associations 
and non-governmental consumer/environmental protection organisations. The European 
Commission's Joint Research Centre facilitates and chairs the meetings of the sub-group and 
prepared this report. Representatives of other relevant Commission services and EU Agencies are 
invited to attend the meetings as observers.   
 
The scope of the present report is to capture the experts' opinions on key scientific issues relevant to 
the identification of endocrine disrupting substances (EDs) in order to support the ad-hoc group 
discussion and the Commission’s decisions on the establishment of horizontal criteria for the 
identification of EDs for use in different regulatory contexts. It was agreed that the ED EAG was not 
required to reach consensus and may present differing opinions and options for consideration by the 
ad hoc group.  
 
The ED EAG identified a number of key scientific reference documents as a basis for the discussion 
including the State of the Art Assessment of Endocrine Disrupters from Kortenkamp et al 2011 (SoA 
report), the IPCS/WHO State of the Science Report from 2002 (2012 update not being available at the 
time of the discussions) and two OECD documents from 2012, these being a guidance on use of 
standardised test guidelines for evaluating endocrine disrupters and a review of the state of the 
science of novel in vitro and in vivo assays for evaluating endocrine disrupters.  
 
The Expert Group accepted the use of the current international definition of an endocrine disrupter 
from IPCS/WHO as a working definition to stimulate discussion by analysing each of the elements 
within the definition. In addition, it was agreed to take as a starting point for discussion the factors or 
elements (described below) identified in the SoA report under decision criteria for the regulation of 
endocrine disrupting properties. During the discussion it became obvious that some of the proposed 
factors were connected to the identification of EDs, while other factors were more connected to a 
characterisation of the hazard posed.  
 
The ED EAG agreed that the elements for identification of an endocrine disrupter were 
demonstration of an adverse effect for which there was convincing evidence of a biologically 
plausible causal link to an endocrine disrupting mode of action and for which disruption of the 
endocrine system was not a secondary consequence of other non endocrine-mediated systemic 
toxicity. Relevance of the data to humans should be assumed in the absence of appropriate data 
demonstrating non-relevance. In relation to wildlife populations, data on all species are generally 
considered relevant. Relevance is instead applied in the context of identified adverse effects being 
relevant at population rather than individual level. 
 
Factors such as potency, severity, irreversibility and lead toxicity were considered not part of the 
identification but rather inform on characterization of the hazard of EDs. The human health experts 
agreed that all the factors were relevant for hazard characterisation and could play a role in ranking 
and priority setting. Some experts supported using the information for differentiating EDs into 
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classes or categories of lower or higher concern (acknowledging that deciding on where to place a 
potency cut-off would be a policy decision) and some experts did not support the use of the 
information for this purpose but considered that the information could only be used within a risk 
assessment context. With respect to ecotoxicological assessment, there was no agreement on how 
to consider these factors with respect to hazard characterisation of EDs outside the context of risk 
assessment. 
 
The ED EAG discussed a basic scheme for the consideration of available evidence and for building 
evidence on endocrine disrupting properties of substances. The ED EAG supported consideration of 
mode of action and adversity in parallel applying weight-of-evidence approaches, weighing all 
available evidence, both positive and negative, including human epidemiology data, field data, 
animal experimental (eco)toxicology studies, in vitro data, (Q)SAR, analogue and category 
approaches to reach a conclusion.   
 
The ED EAG was not able to provide a full evaluation of the adequacy of the currently available test 
methods in the time available. However, it was observed that currently available OECD standardised 
tests within the OECD Conceptual Framework for the testing and assessment of endocrine disrupters 
are mostly focused on the identification of substances acting by interference with estrogen, 
androgen or thyroid hormone pathways, including steroid hormone production, for mammals, fish 
and possibly amphibians, but not for birds or invertebrates. Existing standardised assays might miss 
some endpoints sensitive to endocrine disruption and it was acknowledged that there was no 
standardised assay currently available in mammals that allows the investigation of early life/in utero 
exposure on effects which may appear in later life stages, such as cancer incidence, impact on 
menopause, senescence etc. Further work to identify relevant in vivo biomarkers indicative of 
endocrine activity to augment existing assays was recommended. It was also recommended that 
priority areas for further development of assays to investigate specific endocrine pathways should be 
informed by emerging human health issues or observed negative impacts on wildlife populations and 
hypothesised link to endocrine-related causes.  
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1.   INTRODUCTION  
 
The European Commission, under Directorate-General for Environment (DG ENV),  has established in 
2010 an ad hoc group of Commission Services, EU Agencies and Member States under the 
Community Strategy for Endocrine Disrupters (COM(1999)706) to exchange information on 
endocrine disrupters, to assist the Commission in shaping future policy in this area and to promote 
coordination with the view to ensure an integrated, coherent and consistent approach to dealing 
with endocrine disrupters across the different regulatory frameworks.  
 
The ad hoc group works at the interface between science and policy providing an appropriate forum 
for information exchange on endocrine disrupters, for bringing science on endocrine disrupters and 
chemicals’ policy together, for discussing horizontal aspects of regulation of endocrine disrupters and 
for providing orientation to the European Commission on development and implementation of EU 
policy in this field. At its 2nd meeting held in May 2011 the ad hoc group agreed to establish an expert 
sub-group tasked with making detailed reflections on the scientific issues and in particular on 
providing advice/orientation to the ad hoc group on the scientific criteria for the identification of 
endocrine disrupters.  
 
1.1 Terms of Reference of the Endocrine Disrupters Expert Advisory Group (ED EAG) 
 
Although no formal terms of reference were adopted the main purpose of the ED EAG was 
described and agreed at the 3rd ad hoc group meeting and 1st meeting of the ED EAG held back-
to-back on 16 & 17 November 2011 to be as follows: 
 To provide detailed reflections on scientific issues including advice/orientation on scientific 
criteria for the identification of EDs. 
 To provide a forum for information exchange and discussing scientific aspects to facilitate 
consistent, coherent approaches to identification and assessment of EDs. 
 To provide generic advice not specific to any regulatory framework. 
 To feed output into the ad hoc group where science and policy issues interface. 
In addition it was recommended that participants to the ED EAG should have an (eco)toxicology 
background, preferably with a regulatory background and/or specific experience in 
endocrinology. 
It was clarified and agreed that the ED EAG was not required to reach consensus and may 
present differing opinions and options for consideration by the ad hoc group.  
 
In relation to the ED EAG composition Member State Competent Authorities for REACH1 
(CARACAL) and PPPR2 (Standing Committee), relevant Industry Associations and NGOs could 
nominate up to 2 experts each. The European Commission's Joint Research Centre facilitated and 
chaired the meetings and prepared this report. Representatives of other relevant Commission 
services and EU Agencies were invited to attend the meetings as observers. Other experts could 
be invited (by the Commission) as appropriate.  
 
Additional terms were that: 
 The ED EAG would work by e-mail and have face-to-face meetings  
 The activities of this group would be reported to every meeting of the ad hoc group.  
 
                                                 
1
 Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation (EC) No.1906/2007, 
OJ L136, 3-280 
2
 Regulation (EC) No. 1107/2009 concerning the placing of plant protection products (PPP) on the market, OJ 
L309, 1-50 
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The ED EAG agreed to take the State of the Art report by Kortenkamp A, et al., 2011 
(commissioned by the European Commission) (from now on referred as the SoA report) as the 
basis for the further work taking the first 3 stages of the decision criteria as a starting point for 
organising the discussions at the following meetings. These stages were: 
 Stage 1: Adversity and Mode of Action 
 Stage 2: Human and wildlife relevance 
 Stage 3: Toxicological Evaluation (potency, lead toxicity, specificity, irreversibility and 
severity) 
 
A small working group of volunteering experts within the ED EAG was assigned to act as a 
planning committee to assist in the preparation of the meetings. 
Although the value of discussing human health and wildlife issues together was recognised, it 
was agreed that the most practical and efficient way of working was to have separate parallel 
sessions at the meetings for the human health and the environmental aspects with a common 
plenary session to discuss overarching issues. 
With respect to the specific deliverable of an advisory report on scientific criteria for the 
identification of EDs for further regulatory use, June 2013 was proposed as the target date (later 
revised to March 2013), with December 2012 proposed as a target for a draft report.  
The participants of the ED EAG agreed with the objectives as outlined. 
 
1.2 Scope of the report  
 
The scope of the present report is to capture the experts' opinions on key scientific issues 
relevant to the identification of endocrine disrupting substances (EDs) in order to support the ad 
hoc group discussion and the Commission’s decisions on the establishment of horizontal criteria 
for the identification of EDs for use in different regulatory contexts. Factors considered relevant 
to characterisation of identified EDs with respect to level of concern were also discussed.  
In order to identify key scientific issues, the state of the art report (Kortenkamp et al, 2011) and 
the factors identified in the report were used as a basis. During the discussion it became obvious, 
that some of the factors are connected to the identification of EDs, while other factors are more 
connected to characterisation of the hazard posed. The report also captures this discussion. 
 
1.3 Structure of the report  
 
The structure of the present report was designed to support its scope, meaning to facilitate 
further the discussion of the ad hoc group and the Commission's decisions. In order to achieve 
this aim it was considered appropriate to focus on the factors most important to identification 
and characterisation of EDs, and represent the experts' views in a transparent and unbiased way.  
 
The first two chapters are dedicated to the terms of reference, and the presentation of the terms 
and definitions used to guide and underpin the further discussions. Chapter 3 starts with factors 
relevant for the identification of an endocrine disrupting substance followed by a discussion 
about other factors which might be relevant for hazard characterization of such EDs. Chapter 4 
presents the discussion in relation to the SoA Report's suggested scheme for the evaluation of 
EDs and weight of evidence approaches to assessment of available data. In chapter 5 the 
currently available tools and methods for assessing EDs are briefly discussed. This is followed by 
a brief discussion of which additional test methods might be needed, as well as the need for 
further research into other possible endocrine-related adverse effects and modes of action. 
 
It was considered more appropriate to combine the different discussions for the human health 
and the environment together, providing exemplifications from each of the disciplines of the 
points discussed, where appropriate, and highlighting differences where they existed.  
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1.4 Background material 
 
As agreed the "State of the Art Assessment of EDs" report (Kortenkamp A, et al., 2011) was used 
as one of the main reference documents for the discussion.  
 
The following literature, amongst others, was also used as reference material:   
 The Detailed Review Paper (DRP) on the State of the Science on Novel In Vitro and In Vivo 
Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors, Series on 
Testing & Assessment No. 178 (OECD 2012a) 
 The OECD Conceptual Framework and Guidance Document on Standardised Test Guidelines 
for Evaluating Chemicals for Endocrine Disruption, Series on Testing & Assessment No. 150 
(OECD 2012b)  
 The IPCS mode of action and human relevancy framework (Boobis, et al, 2009)  
 The IPCS/WHO "Global assessment of the State-of-the-Science of Endocrine Disruptors 
report" (IPCS/WHO 2002)3 
 The article from Klimisch et al. for evaluating the quality of experimental toxicological and 
ecotoxicological data (Klimisch H.J., et al., 1997) 
 
1.5 Case Studies 
 
The use of substance-specific case studies as a tool for exemplifying the critical issues within each 
of the topics was generally accepted. The choice of appropriate substances to reveal data gaps 
and relevant issues was emphasised. It was considered that the application of discussed factors 
for ED identification to real data sets, as provided by the case studies, would help inform the 
discussion and might serve to exemplify where guidance would be required in the future 
application of criteria.  
In order to facilitate the discussion on the adequacy of data and the strength of evidence both 
data-rich and data-poor case studies were selected. For some case studies clear evidence for 
adversity and/or mode of action was available while the data for other cases were considered 
inconclusive. The suite of case studies covered both human health and environment. During the 
discussion of the factors for stages 1 to 3 (as described in the SoA report) the identities of the 
substances were masked in order to avoid possible bias. 
 
2.   DEFINITIONS AND UNDERSTANDING OF BASIC TERMS 
 
2.1 Endocrine Disrupter 
 
The ED EAG accepted the use of the following current international definition of an endocrine 
disrupter from IPCS/WHO as a working definition to stimulate discussion by analysing each of the 
elements within the definition. 
 
“An endocrine disrupter is an exogenous substance or mixture that alters function(s) of the 
endocrine system and consequently causes adverse health effects in an intact organism, or its 
progeny, or (sub)populations” (IPCS/WHO, 2002).4 
2.2 Scope of endocrine system 
                                                 
3
 The WHO/UNEP State of the Science of Endocrine Disrupting Chemicals – 2012 was released too late to be 
taken into account in this report  
4
 The WHO/UNEP State of the Science of Endocrine Disrupting Chemicals 2012 update released February 2013, 
did not propose any modification of the IPCS/WHO 2002 definition. 
http://www.who.int/ceh/publications/endocrine/en/index.html 
   
Page 9 
 
 
In order to apply the above mentioned IPCS/WHO definition of endocrine disrupter which refers 
to an exogenous substance or mixture that alters function(s) of the endocrine system it would 
appear that the scope of the endocrine system would need to be defined. Many descriptions of 
the endocrine system can be found in authoritative sources such as the IPCS/WHO, 2002, State 
of the Science review (IPCS/WHO, 2002) and the OECD report on novel endpoints (OECD 2012a) 
including reference to both the components and the function of the endocrine system. The 
endocrine system could be considered as regulating all biological processes in the body by 
synthesising chemical messengers (hormones) in one tissue which are transported (by the 
circulatory system) to other tissues in which they produce their physiological effects. Thus the 
endocrine system could be considered to encompass the hormone-producing tissue, the specific 
target receptors, transport proteins and associated enzymes. According to the SoA report 
(Section 2.1, p.13) "The three important endocrine axes are the hypothalamus-pituitary-gonad 
(HPG) axis, the hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-thyroid 
(HPT) axis. These axes describe the boundaries within which the endocrine system and endocrine 
disruption have been confined from the perspective of classical endocrinology. However, the 
scientific advances in our understanding of receptor signalling and molecular biology are 
continuously blurring the borders between the nervous system, immune system and endocrine 
system. …….An implicit understanding of the endocrine system or endocrine signalling can 
therefore span from the classical definition of the endocrine system to one that encompasses any 
type of receptor-mediated signalling." 
Interest has been focused so far primarily in relation to reproductive and developmental toxicity 
via perturbations of the estrogen, androgen and thyroid hormone (EAT) pathways. Assays have 
been developed and validated at OECD which mainly address the ability of chemicals to interfere 
with EAT signalling processes and steroidogenesis. In consideration of other endocrine pathways 
which may also be susceptible to disruption by environmental chemicals, the OECD recently 
commissioned a review (OECD 2012a), in which the authors were tasked with identifying novel 
assays and endpoints that could be used for assessing whether or not chemicals might have 
endocrine-disrupting activity beyond EAT pathways and steroidogenesis. Evaluations covered not 
only the HPA, HPG and HPT endocrine axes but also the somatotropic axis and the retinoid, 
vitamin D and peroxisome proliferator-activated receptor (PPAR) signalling pathways. Whilst 
acknowledging that the ligands to some of these receptors did not fit the conventional view of a 
hormone (e.g. retinoids and fatty acids), the authors considered that they did fit into the broad 
definition of a hormone described by Thomas (1984) as "a substance, originating in one tissue 
and conveyed by the bloodstream to another to effect physiological activity". 
 
The SoA report also raises the question in the ecotoxicological context of whether the term 
“endocrine system” should be interpreted in the very narrow sense of the hormonal system of 
vertebrates or whether it should include not only invertebrates, but also microbes and plants. 
In answer to this question the ED EAG concluded that even if it were desirable to address 
endocrine disruption across all taxa, based on current knowledge it is not possible to define the 
limits of the endocrine system for all environmental species. From a pragmatic point of view 
there are methods and tools available and known adverse outcomes for EAT pathways for certain 
species. Thus the definition of the endocrine system must include the existing knowledge (EAT 
pathways and steroidogenesis), but must be relatively open and flexible in order to cover less 
known and newly or still to be discovered endocrine system elements in several taxa (e.g. 
ecdysteroids for moulting and egg maturation in crustaceans and insects, juvenile hormones to 
regulate metamorphosis and reproduction, neuropeptides to regulate metabolism or diapause in 
insects and all other invertebrate endocrine systems). 
 
Overall, the Expert Group supported the notion of a broad definition of the endocrine system 
that would not require constant updating as knowledge develops. However, it was acknowledged 
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that currently the possibilities for identifying an endocrine disrupting mode of action were largely 
confined to the EAT pathways as well as interference with steroidogenesis, where mechanistic 
assays have been developed and validated  
 
2.3 Adversity  
 
Another element of the IPCS/WHO definition of endocrine disrupter is "adverse health effects". 
The concept of adversity within toxicology and the point at which an observed change should be 
considered adverse is a topic of continuous debate and the IPCS has adopted a general definition 
not specific to endocrine disrupters as follows: 
 
"A change in the morphology, physiology, growth, development, reproduction or lifespan of an 
organism, system or (sub)population that results in an impairment of functional capacity, an 
impairment of the capacity to compensate for additional stress or an increase in susceptibility to 
other influences" (IPCS/WHO, 2009). 
 
This IPCS definition of an adverse effect includes consideration of a population level effect. Since 
the protection level is set at the population level for environmental assessments, for an effect to 
be considered adverse it should have the potential to impact at the population level (Suter et al., 
1993; EFSA, 2010c). The protection of the population requires the protection of all (sensitive) life 
stages. The ED EAG accepted the IPCS definition of an adverse effect as a working definition on 
which to base the further discussions. 
 
2.4 Endocrine Mode of Action  
 
The IPCS/WHO definition of an endocrine disrupter refers to "an alteration of the function of the 
endocrine system". A substance may cause such an alteration by many different "modes of 
action". The term "mode of action" has been used by IPCS within the specific context of the 
mode of action and human relevancy framework to refer to how a substance interacts with a 
biological system to produce an adverse effect. In this context mode of action is defined as 
follows: 
    
"The biologically plausible sequence of key events, starting with the interaction of an agent with a 
cell, through functional and anatomical changes leading to an  observed effect supported by 
robust experimental observations and mechanistic data" (Boobis et al, 2009).  
In addition "Mode of action differs from mechanism in that the latter implies a more detailed 
understanding of the molecular basis of the toxic effect" (Seed at al, 2005). 
 
2.5 Proof of causality  
 
In deconstructing and analysing the elements of the IPCS/WHO definition of an endocrine 
disrupter a causal association between an alteration of the function of the endocrine system and 
the adverse health effect is provided by the term 'and consequently causes'. Whilst 
acknowledging that absolute proof of causation might be too high a requirement in establishing 
a substance as an endocrine disrupter, a biologically plausible linkage between the activity of the 
chemical in producing the alteration of the endocrine system and an observed adverse effect 
would need to be accepted as the most likely underlying explanation. Such a causal chain of 
events from initial interaction of a substance with its target site in the organism through to the 
adverse outcome was seen to be encapsulated in the definition of mode of action (Boobis et al, 
2009) and are key in the development of Adverse Outcome Pathways (Ankley et al., 2010). 
During the discussion it became obvious, that the type and amount of information needed to 
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demonstrate a biologically plausible linkage depend on the mode of action and the type of 
effects observed (see discussion under 3.1.2, 3.1.3 and 4). For example, even where data for 
several species are available, with in vitro data sometimes indicating several different potential 
modes of action, a causal link and proof of adversity often may only be possible for one, well 
understood adverse outcome pathway (e.g. ER-mediated impairment of fish reproduction, where 
ER-binding/VTG-induction/induction of testis-ova/skewed sex-ratio could be a plausible series) 
and for one species. Sometimes adverse effects are difficult to link to modes of action, even 
though mode of action as well as adversity point towards endocrine disruption.  
 
2.6 Endocrine Activity  
  
The term endocrine activity is often used to refer to substances capable of interacting with the 
endocrine system, e.g. by binding to and activating or blocking steroid receptors, but for which 
evidence linking such activity to an adverse effect is currently lacking, i.e. there is no evidence of 
endocrine disruption in accordance with the IPCS/WHO definition.  
A report of EFSA's Endocrine Active Substances Task Force uses the term endocrine active 
substance (EAS) "to describe any chemical that can interact directly or indirectly with the 
endocrine system and subsequently result in an effect on the endocrine system, target organs and 
tissues." and adds "Whether the effect is adverse or not will depend on the type of effect, the 
dose and the background physiological situation" (EFSA, 2010a).  
 
 
3.    FACTORS CONSIDERED 
 
In the SoA Report (Kortenkamp et al, 2011) it is stated in relation to the IPCS/WHO definition for an 
endocrine disrupter that “there are clearly two requirements for a substance to be defined as an 
endocrine disrupter, namely that of the demonstration of an adverse effect and of an endocrine 
disrupting mode-of-action”. The SoA report under Section 7.2, Decision criteria for the regulation of 
endocrine disrupting properties proposes that weight-of-evidence approaches be applied to 
evaluation of both adversity and endocrine mode of action in parallel and further suggests that other 
factors (such as relevance, potency, specificity, severity and irreversibility) are considered at 
subsequent stages of a step wise decision criteria approach. The ED EAG discussed each of the 
factors and whether they are relevant with regard to the identification of a substance as an ED or for 
a further hazard characterization of such EDs. The output of the discussions is captured below, 
grouped according to whether the factor is considered to be part of ED identification or further 
hazard characterisation. 
 
3.1 Factors relevant for the identification of a substance as an endocrine disrupter 
 
In line with the SoA report the following factors were considered relevant for the decision 
whether or not a substance is an endocrine disrupter according to the IPCS/WHO definition. 
 
3.1.1 Adversity  
 
A number of questions were posed in consideration of two aspects of adversity, i) when an 
observed change can be considered as adverse (considering the IPCS definition) and ii) what 
types of adverse effects may be endocrine-mediated (or even diagnostic of endocrine disruption). 
The latter is considered relevant with regard to the question whether or not a certain type of 
effect may be clearly endocrine mediated (i.e. diagnostic) or may rule out endocrine activity as 
the effect is clearly not endocrine mediated. 
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With respect to i) when a change can be considered adverse, the IPCS/WHO definition of adverse 
health effect, refers to changes in morphology or physiology leading to impairment of function. 
For example, with regard to human health endpoints, it could be discussed whether a change in 
morphology such as adrenal vacuolation without impairment of the functional capacity of the 
adrenal could be considered as adverse. On the other hand, it was noted that it might be easier 
to conclude a change in morphology as adverse compared to a change in physiology which is a 
dynamic process and deciding when such a change becomes adverse is very difficult. One of the 
roles of the endocrine system is to maintain homeostasis in response to physiological 
modulations. Fluctuations within the normal limits of homeostasis may be considered as 
physiological modulation without adverse consequence. At what point these fluctuations may 
become significant in the absence of an accompanying observable adverse effect on function 
could not be defined and would always be a case-by-case decision. For example a fluctuation in 
thyroid hormones for a short period of time during critical windows of development could lead 
to serious adverse effects. It was considered helpful to know the normal range of fluctuations in 
untreated groups. Positive control studies using a known reference chemical could give useful 
information in this direction in relation to the homeostatic capacity of the system. The 
sustainability of a fluctuation is also an important parameter in the evaluation. If the stimulus is 
constant the fluctuation may be maintained (high or low compared to normal) indefinitely. It was 
considered important to evaluate the possible impacts of such a maintained change of state, 
particularly with respect to the IPCS definition of adversity which refers to a change which may 
impair an organism's capacity to compensate for additional stress. 
In contrast to the human health assessment, the protection goal of environmental assessment is 
the protection of populations rather than the individual (Suter et al., 1993; EFSA, 2010b). Thus, 
for an effect to be considered adverse it should have the potential to impact at the population 
level, including sensitive life stages. With regard to ecotoxicological assessment, effects on apical 
endpoints which are likely to affect the population such as growth, reproduction and 
development are usually considered adverse. Changes in vitellogenin levels in fish can be 
considered as a physiological modulation as well as a biomarker of endocrine activity, however 
the effect is not considered as adverse in itself.  
 
With respect to ii) what types of adverse effects may be endocrine-mediated it was agreed that 
when considering a broad definition of the endocrine system (see Section 2.2) it is difficult to 
assess  which adverse effects are clearly endocrine-mediated or non-endocrine mediated, unless 
there is prior knowledge of the biological processes leading to the adversity. However, since 
standard in vivo toxicity studies are not designed to demonstrate how a substance produces its 
toxic effects, the mode of action is unknown for most substances. 
In assessment of mammalian toxicity in relation to human health, the experts concluded that 
specific endpoints where there is already some knowledge of mode of action such as skin, eye 
and respiratory tract irritation, skin and respiratory sensitisation, mutagenicity and genotoxic 
carcinogenicity can be regarded as endpoints/effects clearly not endocrine-mediated. On the 
other hand, toxic effects on endocrine glands or effects on reproduction or development were 
seen as candidates for adverse effects caused by endocrine disruption. In addition, since every 
organ and system in the body is under some form of hormonal or neuro-hormonal control, it was 
considered important to discriminate between endocrine toxicity as a primary effect of an 
endocrine MoA and endocrine toxicity secondary to other toxic effects not mediated by an 
endocrine MoA [see 3.1.3. Specificity]. 
In consideration of adversity in relation to ecotoxicological assessment it was stated that many of 
the population-relevant endpoints measured in standard Test Guidelines related to reproduction, 
growth and survival are quite generic and it is difficult to exclude any of these adverse effects as 
not endocrine-mediated without some information on mode of action. However, an 
understanding of the level of systemic or generalised toxicity can give an indication of whether 
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effects are specific and therefore more or less likely to have an underlying endocrine disrupting 
MoA. 
There was also a discussion on whether some effects may be both adverse as well as indicative of 
an endocrine disrupting MoA, i.e. whether specific adverse effects or patterns of adverse effects 
could already be identified on the basis of existing knowledge to be diagnostic for endocrine 
disruption. Two specific examples were discussed: 
Example 1. In ecotoxicological assessment a change in sex ratio of fish was seen as both adverse 
and, according to the majority of the experts, highly likely to be a marker of endocrine disruption. 
An example was given of the OECD fish sexual development TG (OECD TG 234) in which 
consistent co-observation of a change in sex ratio accompanied by a change in vitellogenin level 
(biomarker of endocrine activity) has been observed in certain fish species (OECD, 2012b). For 
other fish species than those recommended in the TG the basis for using sex ratio as diagnostic 
of endocrine disruption was unclear. The degree of change in sex ratio would also be a factor in 
weighing the strength of evidence as a complete feminization/masculinisation could be 
considered as diagnostic while only a small change or a delay in sexual differentiation might not.  
Example 2. In humans a pattern of effects known as testicular dysgenesis syndrome including 
hypospadias, cryptorchidism and decreased sperm quality which can also be replicated in 
laboratory mammals by certain chemicals (including hypo- and a-spermatogenesis, atrophy of 
the seminal vesicles and prostate, nipple retention, hypospadia, penis malformations, vaginal 
pouches, ectopic testes and decreased anogenital distance), was seen as highly likely to be 
mediated by an anti-androgenic mode of action. Such a clear pattern of effects occurring 
together was considered by most experts as diagnostic of an endocrine disrupting MoA, however 
others considered that in order to identify a substance as an ED a hypothesised endocrine MoA 
needed to be supported by some relevant mechanistic data in all cases, not only to identify an ED 
but also to further knowledge and understanding of how chemicals alter the function of the 
endocrine system (e.g. the need to populate databases with in vitro/in vivo screens and apical 
studies to understand the correlation between data from these various studies for a better 
prediction when dealing with data poor chemicals).  
A substance disrupting the function of the endocrine system might be expected to lead to a 
spectrum of effects since the endocrine system has many interactions, feedback mechanisms and 
cross-talks with other systems and the possibility exists that several organs and several functions 
in the body might be affected. Such spectrum of effects all contribute to a weight-of-evidence 
assessment of endocrine disruption. An isolated finding may be less convincing but may 
nevertheless be concluded to be adverse.  
  
3.1.2 Endocrine mode of action and causal link to adversity 
 
An exogenous substance may alter the function of the endocrine system through many different 
modes of action including interference with production, transport and metabolism of hormones 
thus altering circulating hormone levels or by disrupting the target receptor function by 
inappropriately activating the receptor (hormone receptor agonist) or by inhibiting the action of 
the receptor (hormone receptor antagonist). A substance may be shown to be endocrinally 
active usually through in vitro mechanistic assays demonstrating for example receptor 
binding/(in)activation or interference with hormone production, however, such activity may not 
be expressed in vivo and the link to an adverse outcome is not provided by evidence of such 
endocrine activity alone. In the context of the IPCS mode of action and human relevancy 
framework (Boobis et al, 2008 & 2009) whereby mode of action is defined as "The biologically 
plausible sequence of key events, starting with the interaction of an agent with a cell, through 
functional and anatomical changes leading to an observed effect supported by robust 
experimental observations and mechanistic data" the causal link is embedded in the definition. 
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The IPCS MoA framework describes a process for laying out the strength of evidence in a 
transparent manner supporting a particular hypothesised mode of action applying modified 
Bradford Hill considerations of association such as biological plausibility and coherence, 
consistency of findings, concordance of dose response relationships and temporal associations 
and most importantly characterisation of uncertainties. The ED EAG considered that the level of 
evidence required by the framework in supporting the sequence of key events leading to 
adversity might be too high a requirement for the identification of an ED for regulatory purposes 
since it was developed within the context of relevancy of adverse effects in animals to humans 
where a high degree of confidence is required that a particular MoA is operative in the animal as 
well as confidence that this MoA is not relevant for humans. Nevertheless it was considered that 
the framework could be adapted to the demonstration of an endocrine disrupting MoA. The ED 
EAG considered that evidence of endocrine activity in vitro, along with evidence of an in vivo 
biomarker of endocrine activity and adverse effect coupled with a biologically plausible 
relationship between the measured parameters should be sufficient to conclude on endocrine 
disruption. The type and amount of information needed at the different levels depend on the 
mode of action considered as well as the type of effect observed, e.g. for an estrogen agonist 
mode of action an increased in vivo vitellogenin level together with in vitro information and 
decreased reproductive success in the absence of systemic toxicity might be enough to conclude 
that the adverse effects are caused by an endocrine (estrogenic) mode of action 
 
3.1.3 Specificity 
 
Specificity in terms of an adverse effect that manifests itself as a consequence of an endocrine 
disrupting mode of action, and not indirectly as a result of other non endocrine mediated 
systemic toxicity was considered to be an integral part of ED identification with respect to 
whether or not the primary MoA for the adverse effect is endocrine-related. 
Apart from identifying EDs as those targeting the endocrine system and circulating hormone 
levels, EDs may also be identified as those affecting hormone targets (i.e. hormone receptors). 
An adverse effect, arising from selective cytotoxicity to hormone producing cells can be 
considered as having arisen via an endocrine disrupting MoA and adverse thyroid effects 
secondary to liver enzyme induction leading to enhanced hormone metabolism was also 
considered to represent adversity arising via an endocrine disrupting MoA. However, non-
specific, marked systemic toxicity where effects on the endocrine system might be observed 
along with other toxic effects should not be considered to be the result of an endocrine 
disrupting MoA in the absence of any other specific information that might be indicative of a 
plausible endocrine disrupting MoA. 
Some guideline studies for both human health and ecotoxicology may not allow a distinction to 
be made between primary and secondary effects. Therefore when considering an endocrine 
disrupting MoA it is important to consider the onset and the time-line of the endocrine-mediated 
chain of events together with the limitations of the available standardised tests (e.g. the 
conclusions related to endocrine disruption and adversity may be very different in a short term 
compared with that of a long term study). 
 
3.1.4 Human and wildlife relevance  
 
It was agreed that it was often difficult to demonstrate convincingly the non-relevance to 
humans of adverse effects observed in the animal models and that the usual approach was to 
assume relevance unless non-relevance to humans could be convincingly demonstrated by, for 
example, applying the guidance provided by the IPCS mode of action and human relevancy 
framework (Boobis et al, 2008).Thus relevance to humans should be assumed by default in the 
absence of appropriate scientific data demonstrating non relevance. 
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In relation to ecotoxicology, data on all species, including mammalian data generated to assess 
human toxicity, are generally considered relevant to the assessment of effects on ecosystems. In 
addition, since ecotoxicological assessment relates to impact at the population level rather than 
the individual level, relevance is applied in the context of identified adverse effects being 
relevant for the population.  
 
3.1.5 Summary 
 
The elements for identification of an endocrine disrupter were agreed to be demonstration of an 
adverse effect for which there was convincing evidence of a biologically plausible causal link to 
an endocrine disrupting mode of action and for which disruption of the endocrine system was 
not a secondary consequence of other non endocrine-mediated systemic toxicity. Relevance of 
the data to humans and wildlife populations should be assumed in the absence of appropriate 
data demonstrating non-relevance. 
 
 
3.2 Factors possibly relevant for the characterization of Endocrine Disrupters 
 
The following factors suggested by the SoA report were considered not relevant for the 
identification of substance as ED but could provide information with regard to the further 
characterization of the hazard of such substances. 
 
3.2.1 Severity of Effect 
 
Both seriousness (in the qualitative sense of the nature of effect) and magnitude (quantitative) 
was considered to be covered by the term severity.  
From the perspective of human health assessment, seriousness should consider consequences 
on quality of life (e.g. infertility, developmental effects or shift in IQ of population) and was also 
considered to be linked to irreversibility in relation to the nature of effect. It was considered that 
EDs once identified based on adverse effect and endocrine MoA may be further differentiated in 
relation to the severity of the adverse effect. The experts agreed that severity is not part of 
identification but rather informs on hazard characterisation. The magnitude of the effect at a 
given dose was linked to potency (discussed below) whereas the seriousness of the effect was 
linked to level of concern regarding impact on environment and society and therefore more 
relevant to risk management considerations.   
 
With respect to ecotoxicological assessment, most of the experts considered that severity 
(magnitude and nature of effect) was properly addressed by the concept of adversity (any effects 
considered adverse at population level being by definition severe), and that further grading was 
not required. One expert thought that the magnitude of an effect could be a measure of severity 
and thus could be used for further characterizing an ED (e.g. a small reduction in reproduction 
compared to zero reproduction, where both are considered adverse but differentiation on the 
basis of the magnitude of the adverse effect can be made). To characterize an ED based on the 
nature of the effect was considered difficult as the test and endpoints measured are indicative of 
effects on the population level and it is thus difficult to correlate nature of effect with potential 
impact at population level. The experts also discussed whether or not with regard to the 
environment the number of species affected might be a factor to characterize an ED. However 
the experts concluded that such a differentiation would be difficult as even if only a small 
proportion of species is affected they might be of high relevance for the ecosystem.  
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3.2.2 Irreversibility 
 
In terms of the hazard characterisation, irreversibility was considered to be part of severity in 
relation to the nature of the effect. It was considered that even where an adverse effect might be 
reversible following cessation of exposure, in considering a continuous emission exposure 
scenario the possibility for recovery was not provided thus the issue of determining within an 
assessment whether an effect was reversible or not was not so important. However in terms of 
the possibility of treatment and recovery of an individual or population following identification 
and removal of the causative factor, or in the case of persistent chemicals the lack of ability to 
remove the causative factor, knowledge of the irreversibility of the effect would be extremely 
important information in relation to level of concern regarding impact on environment and 
society and therefore more relevant to risk management considerations. In addition, for known 
and well described non-continuous exposure scenarios (e.g. plant protection products) 
knowledge on potential reversibility of an effect may be important in relation to level of concern. 
However, it was emphasised that current (eco)toxicity test guidelines are often not designed for 
determining whether effects are reversible or not, thus limiting the possibility to address this 
issue. In addition the reversibility/irreversibility of an effect may depend on the timing of 
exposure (e.g. in adult life or during a critical time of development such as during pregnancy 
when hormones are triggering organ differentiation). 
 
3.2.3 Lead toxicity 
 
Substances may produce different effects at different dose levels by different modes of action in 
the same species. Lead toxicity is the effect that occurs at a lower dose than other toxic effects, 
i.e. the most sensitive or dominant feature of the hazard profile of a substance. Lead toxicity is 
generally used in risk assessment to identify the most sensitive endpoint (i.e. critical effect) as a 
point of departure for risk assessment. The premise is that when conducting a risk assessment on 
the effect seen at the lowest dose level this will also protect the individual or population from 
effects occurring at higher dose levels. However this would only be applicable to endpoints for 
which a threshold approach was considered appropriate and where there is confidence that the 
toxicity studies have covered critical windows of exposure and relevant endpoints for endocrine 
disruption. The experts agreed that lead toxicity is not relevant for hazard identification (i.e. if 
adverse effects are observed which are clearly endocrine mediated, the substance should be 
identified as ED irrespective of whether or not the endocrine-mediated effects are the most 
sensitive effects), but some human health experts considered it may have a role in hazard 
characterisation. For example, if non endocrine-mediated toxicity was expressed at 
concentrations orders of magnitude lower than the dose producing the endocrine-mediated 
effect this may inform under hazard characterisation on the potential importance of this 
endocrine-mediated effect to the overall toxicity profile of the substance but this would depend 
on the type of effect at the lowest dose and the dose spacing.  
Other human health experts argued that it can be difficult to identify the lowest effect level 
caused by endocrine disruption, because of the possibility of non-monotonic dose responses. In 
addition, it was noted that even endocrine-mediated effects not arising at the lowest adverse 
effect dose level can contribute to additive effects on co-exposure to other substances acting via 
similar modes of action or causing common adverse outcomes. 
In ecotoxicological assessment it may be difficult to separate endocrine-mediated adverse effects 
from non endocrine-mediated adverse effects within the same species, since different types of 
toxicity in different target organs, which could help to conclude that one adverse endpoint is 
endocrine-mediated and another is not, are generally not assessed. Hence the majority of the 
experts concluded that it is difficult to use lead toxicity for further characterisation of the hazard 
profile within a particular species. However, where diagnostic measures of endocrine activity are 
also measured in higher tier tests it may be possible distinguish between specific effects having 
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an underlying endocrine mode of action from those effects caused by other modes of action. As 
such lead toxicity, was considered by some experts, as a tool to inform hazard characterisation. 
Lead toxicity might also be interpreted in the ecotoxicological context in the sense of sensitivity 
across species, however, such taxonomic specificity was not discussed by the experts. 
 
3.2.4 Potency 
 
From a scientific point of view it was agreed that potency considerations were not part of the 
identification of a substance as an ED but rather play an important role in hazard characterisation, 
by characterising the dose/concentration-response. The experts discussed whether or not such 
considerations were relevant, along with other factors such as severity and irreversibility, in 
identifying the level of concern for regulatory purposes.  
 
In the human health sub-group, it was agreed that although potency was useful for 
characterising EDs and ranking them in order of concern, an appropriate potency cut-off value 
between higher concern and lower concern EDs could not be scientifically determined and it 
would be primarily a policy decision on where to place the cut off.  
In relation to defining such categories of lower and higher concern, approximately half of the 
human health sub-group considered that potency couldn’t be used for categorization while the 
other half considered that potency should be taken into account for categorization in 
combination with other factors such as irreversibility and severity.  
In the environment sub-group, there was no consensus on the use of potency for hazard 
characterization. In line with the human health sub-group, it was agreed that an appropriate 
potency-based cut-off between higher concern and lower concern EDs could not be scientifically 
determined. The sub-group further agreed that potency alone should not be used for the 
characterization of EDs. Some of the experts felt that it cannot be used at all while other experts 
considered potency to be an extremely important factor in characterisation together with other 
factors such as severity and irreversibility. 
 
3.2.5 Summary 
 
Factors such as potency, severity, irreversibility and lead toxicity were considered not part of the 
identification but could inform on characterization of the hazard of EDs. For the human health 
experts it was considered that these hazard characterisation factors may be used in combination 
to rank EDs according to "level of concern", which could be used by risk managers for 
prioritisation purposes, however, it was not discussed how these factors could be used together 
to define different categories of EDs. Half of the human health sub-group were in support of 
using these factors for creating categories of EDs of higher or lower concern with the prospect of 
different regulatory consequences applied to each category. These experts referred to the 
hazard classification criteria under Regulation (EC) No 1272/2008 on classification, labelling and 
packaging (CLP) of substances and mixtures as a good model to follow. In the CLP Regulation, 
differentiation between Categories 1a/b and 2 for substances classified as carcinogenic, 
mutagenic or toxic for reproduction (CMR) is primarily related to levels of evidence for the 
probability of the effect occurring in humans, but there are also elements related to severity of 
effect (ECHA 2012). Notably the CLP Regulation uses guidance values for sub-categorisation of 
specific target organ toxicity – repeated exposure (STOT-RE) but not for CMRs.  
 
With respect to ecotoxicological assessment, there was no agreement on how to consider lead 
toxicity, severity or potency with respect to hazard characterisation of EDs outside the context of 
risk assessment. Some experts considered that severity could be used in a weight of evidence 
approach, while the majority considered that it was not useful. For potency some felt it could not 
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be used at all while others considered it could be used along with the other factors in a weight-
of-evidence approach on a case by case basis. 
 
Hazard characterisation, following hazard identification, is a critically important step in risk 
assessment in the context of derivation of acceptable exposure levels, however, as risk 
assessment is not carried out for identified EDs under the PPPR and BPR5 then some experts had 
difficulties to see how the discussed factors relevant for hazard characterisation could be applied. 
According to some of the experts, not considering hazard characterisation for EDs under the 
PPPR and BPR would mean to ignore available scientific data.  
Some of the experts proposed that although the elements of hazard identification (ED MoA, 
adversity, specificity, relevance) are the basis for the scientific definition of an ED, the elements 
of hazard characterisation should be taken into account in relation to regulating EDs. These 
elements of hazard characterisation represent considerations of the science; however, their 
application in differentiating between EDs of higher or lower concern outside a risk assessment 
context goes beyond science. Therefore, it is for risk managers and policy makers to decide to 
which extent to apply these elements of hazard characterisation in developing regulatory criteria 
for the identification and categorisation of EDs of regulatory concern. If it were decided to 
include these elements in regulatory criteria clear guidance on their application would need to 
be developed. Some experts considered that although prioritisation on the basis of hazard 
characterisation is often accepted, “level of concern” should be ultimately based on a risk 
assessment, i.e. including exposure considerations, since the risk from a low potency chemical 
can be higher than from a highly potent chemical if exposure to the low potency chemical is high 
enough to provoke an effect and exposure to the highly potent chemical is so low that no effect 
is produced. 
 
 
4.    SUGGESTED SCHEME FOR THE EVALUATION OF EDs 
 
4.1 Basic Scheme  
 
4.1.1 ED identification 
 
The ED EAG supported a decision scheme which captures both demonstration of an adverse 
effect linked to convincing evidence for an associated endocrine disrupting mode-of-action as 
being the 2 main elements for the identification of an ED. It was also considered that specificity 
was part of ED identification, since it was agreed that the primary mode of action of a substance 
should be disruption of the endocrine system rather than the disturbance of the endocrine 
system being a secondary consequence of other non endocrine-mediated systemic toxicity.  
Relevance of the adverse effect and related mode of action to humans or relevance of the 
endocrine-mediated adverse effect at population level with respect to wildlife was also 
considered to be a decision criterion for ED identification.   
These elements were considered sufficient for the scientific definition of an ED, however, some 
experts expressed the view that the elements of hazard identification alone (and in particular 
adversity and endocrine disrupting MoA alone) were insufficient to define a confirmed ED for 
regulatory purposes, respecting that it is for risk managers and policy makers to decide to which 
extent to apply elements of hazard characterisation in developing regulatory criteria for the 
identification of EDs of regulatory concern. 
 
                                                 
5
 Regulation (EU) No.528/2012 concerning the making available on the market and use of biocidal products 
(BPR), OJ L167, 1-123 
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The matrix from the SoA report graphically representing the level of evidence for adverse effects 
on one axis and level of evidence for endocrine disrupting MoA on the other was considered to 
be a potentially useful visualisation tool to show how MoA and adversity should be considered in 
parallel and not in sequence (see Figure 1).  
 
 
 
 
Figure 1: Matrix for evaluating evidence for adversity and endocrine mode of action in parallel 
(from Kortenkamp et al, 2011. Section 7.2.2, p.127) 
  
It was accepted that the 4 scenarios represented by the 4 quadrants in the matrix, respectively, 
strong evidence for adverse effects/strong evidence for endocrine disrupting MoA; strong 
evidence for adverse effects/weak evidence for endocrine disrupting MoA, weak evidence for 
adverse effects/strong evidence of endocrine disrupting MoA; weak evidence for adverse 
effects/weak evidence for endocrine disrupting MoA may arise and the ED EAG considered the 
type of evidence likely to lead to inclusion in each quadrant and how to proceed or conclude in 
each case as described below. It was assumed that the starting point for using the matrix would 
normally be either some evidence of endocrine activity or some evidence for an adverse effect 
hypothesised to be caused by an endocrine disrupting mode of action. The scheme could be used 
not only to evaluate available data but also to identify data gaps and build evidence. The ED EAG 
stressed that in order to consider a substance as a confirmed ED (i.e. to be placed in lower right 
quadrant of the matrix) the evidence for both adverse effect and endocrine disrupting mode of 
action must incorporate the evidence for a biologically plausible causal relationship between the 
endocrine activity and the observed adverse effect(s). Some experts also preferred the terms 
insufficient evidence in place of weak evidence and sufficient evidence in place of strong evidence. 
 
Confirmed  ED – strong (sufficient) evidence for adverse effect(s)/strong (sufficient) evidence 
for endocrine disrupting MoA (lower right quadrant). 
A substance for which there is sufficient evidence of an adverse effect or pattern of effects for 
which human or ecotoxicological relevance could not be ruled out and for which there was 
sufficient evidence that the adverse effect arose from an alteration of the function of the 
endocrine system, rather than arising as a secondary consequence of marked generalised non-
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specific toxicity at high dose levels, was considered sufficient to conclude that a substance is an 
ED. 
 
Strong evidence for adverse effect(s)/weak (no) evidence for endocrine disrupting MoA (upper 
right quadrant) 
Substances for which there was clear evidence of adverse effects but for which the evidence 
linking the adverse effect or pattern of effects to an endocrine disrupting mode of action was 
considered insufficient to conclude, would reside in this quadrant. In these cases there may be 
evidence of endocrine activity in vitro but no plausible link to the pattern of adverse effects 
observed. Further investigations specifically linked to determining the hypothesised mode of 
action would normally be required in such cases.  
 
Possibilities for further testing may include conducting the battery of available in vitro assays 
covering EATS modalities within the OECD Conceptual Framework (OECD 2012b). Substances 
showing activity in in vitro assays could be supported by ADME data or further investigated in 
appropriate in vivo assays evaluating relevant biomarkers for the type of endocrine activity 
identified.  
It was discussed that there may be clear cases where an adverse effect, or more likely a pattern 
of adverse effects, may be considered to be both adverse as well as directly indicative (i.e. 
diagnostic) of endocrine disruption. Such cases may be moved to the confirmed ED quadrant, 
indicating sufficient evidence of adversity as well as sufficient evidence of an endocrine 
disrupting MoA. However, it was considered that apical adverse effect data were rarely able to 
provide suitable information on the mode of action and in most cases further confirmation of the 
specific MoA by generation of some appropriate mechanistic data would be required. 
Insufficient evidence of an endocrine disrupting MoA may be due to lack of standard assays to 
probe disruption of specific pathways e.g. non-EAT modalities. Specific ad hoc mechanistic 
studies may need to be designed in such cases. 
 
In standard toxicity studies it is required that the test substance is tested up to maximally 
tolerated doses, so adverse effects would be observed in almost all cases, at least at the top dose 
level. Therefore, particular consideration should be given to whether or not these adverse effects 
are likely to be endocrine-mediated, or just a consequence of marked toxicity. Lack of any 
evidence of endocrine activity from the available in vitro assays investigating EATS modalities 
would not necessarily rule out an endocrine disrupting MoA since active metabolites may be 
generated in vivo or the substance may be active via other modalities for which assays are not 
yet available. However, negative results in these assays and the absence of any hypothesised link 
of the adverse effect to any endocrine mode of action according to current knowledge would be 
indicative of no evidence for endocrine disruption.  
 
Weak (no) evidence of adverse effects /strong evidence for endocrine disrupting MoA (lower 
left quadrant ) 
Substances with endocrine activity demonstrated in vitro and confirmed in vivo via appropriate 
biomarkers might be expected to produce adverse effects coherent with the type of endocrine 
activity observed. If the expected adverse effects are observed this should be sufficient to move 
the substance into the confirmed ED quadrant, however, if not observed it has to be considered 
whether the appropriate assay, covering the critical windows of exposure, and appropriate 
observations, in relation to the apical endpoints relevant for assessment of adversity, have been 
conducted.  
The assessment of adversity may be on the borders of whether recorded observations should be 
considered as physiological modulations or as truly adverse. For example, an increase in 
vitellogenin (egg yolk protein) in fish is considered to be a physiological modulation as well as an 
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in vivo biomarker of an estrogenic mode of action. Although not adverse in itself, according to 
the IPCS definition for adversity, it can be correlated with a change in sex ratio, which is 
considered an adverse effect relevant at the population level. Such evidence (i.e. increased 
vitellogenin) would be strongly suggestive of endocrine disruption but in the absence of adversity 
(e.g. change in sex ratio) could not be concluded as an ED. It has not yet been demonstrated that 
changes in vitellogenin are necessarily a population relevant change as they are not always 
associated with altered sex ratio or significant impacts on fecundity, however, some experts 
considered that at some future time, knowledge might become sufficient to be able to equate a 
certain level of vitellogenin reduction or induction with population level effects. 
A measure of anogenital distance (AGD) is also considered an ED-sensitive in vivo biomarker 
which is a morphological change indicating effect on sexual differentiation and increased risk for 
reproductive effects later in life (Bowman et al, 2003; Christiansen, et al, 2008; McIntyre et al, 
2002) but with no known direct effect on function and hence may not be considered adverse 
according to the IPCS definition of adverse effect.  
Some experts questioned whether such a clearly undesirable change in morphology as decreased 
AGD should not be considered as enough evidence to conclude the substance to be an endocrine 
disrupter, especially since AGD may be used in defining the NOAEL according to OECD TG 443 
(EOGRTS). However, this rationale was not supported by the whole of the human health sub-
group since AGD is likely to be accompanied by other effects when used to set a NOAEL and AGD 
as an isolated finding would not be considered as enough evidence to conclude the substance to 
be an endocrine disrupter. 
  
Weak (no) evidence of endocrine disrupting MoA/weak (no) evidence of adverse effects (upper 
left quadrant) 
In such cases where there are no adverse effects for which there is a hypothesised endocrine 
disrupting MoA nor any convincing evidence of endocrine activity a decision not to proceed 
further was supported, however, the term non-ED should not be applied, rather it should be 
stated that there is no evidence that the substance is an ED. Cases of weak evidence of endocrine 
activity may warrant further investigation even in the absence of strong evidence of an adverse 
effect depending on the completeness of the available data. 
 
4.1.2. Further characterisation of identified EDs 
 
Following identification as ED, substances in the lower right quadrant could be further 
characterised according to factors such as magnitude and nature of the effect (severity and 
irreversibility) and dose at which the effect or effects were observed (potency), which could also 
be compared with doses at which other non endocrine-related toxicity occurred. For 
considerations of how to use these data outside a risk assessment context see section 3.2. 
 
 
4.2 Weight-of-Evidence Considerations 
 
4.2.1 Weight of evidence 
 
Weight-of-evidence approaches should be applied in the evaluation of both adverse effects and 
mode of action. Weight-of-evidence approaches generally refer to weighing all available 
evidence, both positive and negative, including human epidemiology data, field data, animal 
experimental (eco)toxicology studies, in vitro data, (Q)SAR, analogue and category approaches in 
order to reach a conclusion.  
Factors that were identified as important in a weight-of-evidence approach to both ED 
identification and characterisation and for either adverse effect or endocrine disrupting MoA 
include the quality, reliability and relevance of the individual studies, as well as consistency and 
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reproducibility of reported effects, the pattern of effects across and within studies, number of 
species showing the same or similar effects, time of onset of effects and life stage affected. 
These factors are not specific to assessment of endocrine disruption, per se, but relevant for any 
toxicity assessment. With respect to reproducibility it was pointed out that such evidence for 
reproducibility is often difficult to obtain from expensive in vivo studies with a high animal 
consumption that are unlikely to be repeated, like reproductive toxicity studies. Adequacy of the 
study with respect to sensitivity and observation of relevant endpoints was also highlighted as 
important. 
With respect to study quality it was agreed all studies should be considered but quality criteria 
were necessary to accept the validity of the reported findings. The SoA report highlights the 
approach developed by Klimisch (Klimisch et al., 1997) for assessment of the quality of 
toxicological studies. According to Klimisch, a study is reliable without restrictions if it is 
generated according to generally valid and/or internationally accepted testing guidelines 
(preferably performed according to GLP) or in which the test parameters documented are based 
on a specific (national) testing guideline (preferably performed according to GLP) or in which all 
parameters described are closely related/comparable to a guideline method. The importance of 
a) GLP as a worldwide accepted lab accreditation system for assuring the appropriate 
documentation of results; b) OECD study guidelines as validated, robust, reproducible methods 
that have been tested in many labs before approval to ensure consistent, valid results; and c) 
worldwide recognition of Test Guideline data under the OECD Mutual Acceptance of Data (OECD 
MAD, 1981) was recognised. Nevertheless, it was proposed that non-guideline data (e.g. from 
academic laboratories) following good scientific principles in design, conduct and reporting and 
employing appropriate statistics, should be judged on their scientific merit and not automatically 
considered of lower quality to a Test Guideline conducted by a GLP accredited facility.  
 
The quality of human epidemiology data was acknowledged to be much more difficult to 
establish because of uncertainties in e.g. exposures, confounding factors, and study size, making 
their interpretation challenging. Nevertheless taking appropriate account of such factors is 
critical to the acceptance of the strength of evidence of the associations described. Bradford Hill 
considerations of causal inference are generally used to help evaluate the reliability and 
robustness of findings from human observational studies. In the last decade human 
biomonitoring programmes have been established in many countries across the globe. The 
modern human biomonitoring studies are well designed with rigorous, scientific approaches to 
data collection, analysis and interpretation. Many uncertainties characteristic of older 
epidemiological studies, such as poorly defined exposure and confounding factors, can now be 
addressed. Therefore these newer epidemiological studies offer scientifically more robust results 
to which Bradford Hill considerations can be applied (Albertini, et.al., 2006; Knudsen & Merlo, 
2012). 
 
For in vitro mechanistic assays used for screening some participants considered that the level of 
validation required for acceptance may not be so critical, provided some quality control could be 
demonstrated e.g. at a minimum there should be appropriate positive and negative controls, and 
reproducibility should be adequately demonstrated. 
 
4.2.2 Mode of action analysis methodology 
 
A specific weight of evidence approach providing a methodology for analysing and transparently 
laying out the evidence for the association of the activities of a chemical with specific adverse 
effects is provided by the IPCS's Mode of Action framework as already described under Section 
3.1.2. The methodology is applicable to the assessment of any mode of action including 
endocrine disrupting MoAs. The concept has also been taken up recently by the OECD in relation 
to Adverse Outcome Pathways (AOPs) as an approach to evaluate and integrate many different 
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types of chemical and biological information following a mode of action-based approach to 
understanding adverse effects (OECD 2012c). OECD have adopted the term Adverse Outcome 
Pathways (AOPs) for this activity, a term which originated in ecotoxicology but for which the 
concept is equally applicable, as is MoA, across both disciplines. 
 
4.2.3 Summary 
 
Weight-of-evidence approaches need to be applied in both evaluating adverse effects and 
endocrine activity, particularly in capturing the weight-of-evidence establishing the relationship 
between endocrine activity and adverse outcomes. There are a number of examples in the 
scientific literature describing weight-of-evidence approaches in general and two specific 
examples describing the application of weight-of-evidence approaches to assessment of EDs is 
highlighted in the SoA report under section 4.1.4.  
Of particular value in the context of evaluating strength of association of an endocrine disrupting 
MoA to an adverse effect is the IPCS mode of action and human relevancy framework, although 
the ED EAG considered that the level of evidence required by the framework in supporting the 
sequence of key events leading to adversity might be too high a requirement for the 
identification of an ED for regulatory purposes (See 3.1.2). The OECD AOP activity also provides a 
structured framework to integrate evidence laying out the sequential progression of events from 
a molecular initiating event to the in vivo adverse outcome of either human or ecotoxicological 
relevance.   
Following adoption of criteria the development of guidance for the application of the criteria 
could use as a basis such weight-of-evidence approaches with appropriate modifications. 
It was noted that for a number of the case studies discussed within the human health sub-group, 
different conclusions might be drawn concerning allocation to any of the 4 quadrants within the 
suggested evaluation scheme, depending on interpretation of the available data sets in relation 
to the assessment criteria. This underscores the need to develop further guidance for application 
of the criteria. 
 
 
5.    TESTING FOR EDs 
 
5.1 Availability and adequacy of current tools and methods for assessment of EDs 
 
The adequacy of current test methods is an issue which needs to be addressed in future in detail, 
as the ED EAG was not able to provide the necessary detailed advice on this in the time available. 
The SoA report could form the initial basis of an evaluation of existing regulatory test methods. 
Discussions focused on the OECD Conceptual Framework (CF) for Testing and Assessment of 
Endocrine Disruptors as revised in 2012 (OECD 2012b, pp385-387) which includes the OECD TGs 
available, or under development that can be used to evaluate chemicals for endocrine disruption. 
The CF is composed of five levels; Level 1 (existing information and non-test information); Level 2 
(In vitro assays providing data about selected endocrine mechanism(s) / pathways(s); Level 3 (In 
vivo assays providing data about selected endocrine mechanism(s) / pathway(s)); Level 4 (In vivo 
assays providing data on adverse effects on endocrine relevant endpoints); Level 5 (In vivo assays 
providing more comprehensive data on adverse effects on endocrine relevant endpoints over 
more extensive parts of the life cycle of the organism). 
 
5.1.1 Adverse Effects  
 
It was agreed that levels 4 and 5 of the updated 2012 version of the OECD Conceptual 
Framework (CF) incorporates the in vivo guideline studies relevant for the identification of 
several adverse effects relevant to endocrine disruption, accepting that in these assays effects 
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can be sensitive to more than one mechanism including non-endocrine disrupting mechanisms. A 
number of OECD Test Guidelines have been updated recently to include additional parameters to 
enhance the sensitivity of the assays to identify endocrine-related effects and hence studies 
conducted according to the old versions of the OECD Test Guidelines may, in some cases, be 
considered inadequate according to current standards. It was also pointed out that non guideline 
data which might be generated in academic labs should not be discounted, provided they follow 
good scientific principles in design, conduct and reporting and employ appropriate statistics.  
Some of the endpoints included in level 3 non-mammalian assays are also considered adverse 
(especially fecundity in the fish short term reproduction assay (TG 229)) but due to the high 
variability and low statistical power it may be difficult to conclude on a NOEC. If effects are 
pronounced enough they may be considered as adverse in a case-by-case decision in a weight-of-
evidence approach. In relation to ecotoxicological assessment, mammalian data should also be 
considered. 
 
5.1.2 Endocrine mode of action and causal link to adversity 
 
In vitro and in vivo assays included within OECD CF levels 2 and 3, respectively, were considered 
to be the currently available validated assays for use in determining an endocrine mode of action. 
It was also accepted that case-by-case ad hoc mechanistic studies may also be required, 
especially for possible endocrine modes of action where validated assays were not yet available.  
 
Some in vivo biomarkers indicative of endocrine activity, within OECD CF levels 4 and 5 assays 
could be also informative in relation to the endocrine mode of action. Read-across from 
mammalian to non-mammalian mechanistic studies and vice versa was also indicated as 
contributing to the building of evidence for an endocrine mode of action, when appropriate. 
Data generated under the US EPA Endocrine Disruptors Screening Program (USEPA EDSP) was 
suggested as potentially providing a valuable resource in relation to mode of action which may 
inform on further testing and testing strategies for other chemicals. 
 
5.1.3 Summary 
 
Currently available OECD tests within the OECD Conceptual Framework for the testing and 
assessment of endocrine disrupters are mostly focused on EAT modalities as well as 
identification of substances acting by interference with steroidogenesis, for mammals, fish and 
possibly amphibians, but not for birds or invertebrates. With regard to birds and invertebrates no 
OECD tests are available which include biomarkers for endocrine activity and the limited 
knowledge makes it difficult to conclude whether or not effects are endocrine-mediated. 
Nevertheless, some non-OECD study findings might be sufficient to reach a positive conclusion 
for endocrine disruption in these species. In some cases it may be possible to reach a conclusion 
based on a single test (e.g. TG234 for fish, TG416 (two generation reproduction assay) or TG443 
(EOGRTS) for mammals). 
 
5.2 Further research needs 
 
With regard to adverse effects/apical endpoints relevant to human health assessment, some 
participants considered that the currently available standardised guideline studies are adequate 
in most cases, especially for EATS modalities, since, despite the fact that the existing assays might 
miss some endocrine-sensitive endpoints, substances with endocrine-disrupting activity are likely 
to produce a range of adverse effects (many of which will be observed in an appropriate 
guideline study) because of the complexity of the endocrine system with its multiple signalling 
pathways, feedback mechanisms and cross-talks. 
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Nevertheless it was acknowledged that there are gaps including in particular the lack of an assay 
that covers the full lifecycle from in utero to old age, to allow investigation of early life exposure 
on cancer incidence, impact on menopause, senescence etc. manifested in later life stages.  
Other experts considered that the currently available guideline studies are inadequate in most 
cases. 
 
With respect to ecotoxicological assessments, further work to identify relevant in vivo 
biomarkers indicative of endocrine activity to augment existing assays was recommended (also 
relevant in context of human health assessments). In addition, general knowledge of the 
endocrine system in invertebrates, birds, amphibians, as well as plants and microbes is currently 
limited.  
 
The OECD Detailed Review Paper No.178 (OECD 2012a) points to the lack of certain mechanistic 
assays for the investigation of non EATS modalities relevant to the development of, for example, 
metabolic syndrome. 
Annex III of the SoA report was considered to provide a comprehensive compilation of human 
health and wildlife adverse effects for which there is evidence or suspicion of an endocrine 
disrupting mode of action. These effects are matched against the existence of equivalent 
endpoints or markers in available animal models, specifying which OECD TGs include the 
endpoints as well as whether they cover the critical windows of exposure. Relevant biomarkers 
and available assays for endocrine modes of action are also described. 
 
It was recommended that priority areas for further development of assays to investigate specific 
endocrine pathways should be informed by emerging human health issues or observed negative 
impacts on wildlife populations and hypothesised link to endocrine-related causes.  
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Addendum 
 
One expert (Susy Brescia, Health & Safety Executive, United Kingdom) stated that the final report is 
not a true reflection of all her views although she did provide comments, many of which were 
included in the report. She stated:- 
"This expert disagrees that hazard identification is equivalent to identification of an endocrine 
disrupter (as implied by the report) and hence that hazard characterisation cannot be used, on a 
scientific basis, for identification of EDs. The elements of hazard characterisation are considerations 
of the science and play an important role in the identification of EDs (especially if these EDs are going 
to be regulated in a number of contexts). Hazard characterisation is a critical step of hazard 
assessment; elements of hazard characterisation have been applied for decades and are still applied 
in the toxicological and ecotoxicological hazard identification system of the CLP Regulations." 
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